<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-60636</identifier>
<setSpec>0025-7753</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Seroprevalence study of hepatitis B among orienteers</dc:title>
<dc:description xml:lang="en">Background and objective: Our objectives were to detect asymptomatic cases involved in an outbreak of hepatitis B, to assess the seroprevalence of hepatitis B (HB) in orienteers and to establish recommendations. Patients and method: One hundred sixteen orienteers who had competed in the categories involved in the previous outbreak as well as a stratified random sample of 166 of the remaining orienteers in other competition categories were included in a cross-sectional serological prevalence study. HB surface antigen (anti-HBs); total antibody to HB core antigen (total anti-HBc); HB surface antigen (Ag HBs); and antibody IgM to HB core antigen (anti-HBcIgM) along with the history of vaccination for hepatitis B were analyzed. The results were weighted. Results: The seroprevalence of HB (total anti-HBc positive) was 6.7% (n=12, 95%CI 0.6-12.9). No case of acute HB or chronic infection was observed. All the serological markers were negative for 61.1% (n=64, 95%CI 46.3-75.6), and 31.5% (n=29, 95%CI 18.2-46.4) had markers of immunity due to vaccination. Among individuals under 25 years of age, 28.4% were unvaccinated, although they were covered by vaccination programs. Conclusion: Our results suggest that the seroprevalence of HB among orienteers is not different from the general population in Spain. However, it is necessary to reinforce the vaccination among adolescents and young adults. General recommendations for the prevention of HB were made to orienteering federations (AU)</dc:description>
<dc:creator>García, Luis</dc:creator>
<dc:creator>Echevarria, Jose Manuel</dc:creator>
<dc:creator>García, Miguel Angel</dc:creator>
<dc:creator>García, Visitación</dc:creator>
<dc:creator>Hernando, Victoria</dc:creator>
<dc:creator>Pedro, Ramón</dc:creator>
<dc:creator>Quiñones, Carmen</dc:creator>
<dc:creator>De Mateo, Salvador</dc:creator>
<dc:creator>Soler, Pilar</dc:creator>
<dc:creator>Bleda, María José</dc:creator>
<dc:creator>Castilla, Jesús</dc:creator>
<dc:creator>Gallardo, Virtudes</dc:creator>
<dc:creator>Jardi, Rosendo</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Fundamento y objetivo: Detectar casos asintomáticos relacionados con un brote, valorar la seroprevalencia de hepatitis B (HB) en deportistas de orientación y establecer recomendaciones. Pacientes y método: Se realizó un estudio transversal de seroprevalencia entre 116 deportistas de orientación que habían competido en las categorías implicadas en un brote previo y una muestra estratificada de 166 corredores del resto de otras categorías de competición. Se analizaron marcadores de HB: antígeno de superficie del virus de la HB (VHB) (HBsAg), anticuerpo contra el antígeno core del VHB (anti-HBc), anticuerpos contra el HBsAg, anti-HBc tipo inmunoglobina M y antecedentes de vacunación. Los resultados se expresan utilizando pesos ponderados. Resultados: La seroprevalencia de HB (anti-HBc positivos) fue del 6,7% (n=12; intervalo de confianza [IC] del 95%: 0,6 a 12,9). No se observó ningún caso de HB aguda o crónica. Todos los marcadores fueron negativos para el 61,1% (n=64; IC del 95%: 46,3 a 75,6), y el 32,3% (n=29; IC del 95%: 18,2 a 46,4) tenía marcadores de inmunidad por vacunación. Entre los sujetos menores de 25 años, el 28,4% estaba sin vacunar a pesar de que entraban en el calendario vacunal. Conclusiones: Los resultados muestran que la seroprevalencia de HB entre deportistas de orientación no difiere de la población general. Sin embargo, es necesario reforzar la vacunación entre adolescentes y adultos jóvenes. Se dan recomendaciones generales para la prevención de HB a las federaciones de orientación (AU)</dc:description>
<dc:source>Med. clín (Ed. impr.);132(17): 649-653, mayo 2009. tab</dc:source>
<dc:identifier>ibc-60636</dc:identifier>
<dc:title xml:lang="es">Estudio de seroprevalencia de hepatitis B en deportistas de orientación</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d29315</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d28093^s22001</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d13562</dc:subject>
<dc:subject>^d33343^s22080</dc:subject>
<dc:subject>^d6664^s22069</dc:subject>
<dc:subject>^d6666^s22001</dc:subject>
<dc:subject>^d6665^s22001</dc:subject>
<dc:subject>^d30702^s22000</dc:subject>
<dc:subject>^d31670</dc:subject>
<dc:type>article</dc:type>
<dc:date>200905</dc:date>
</metadata>
</record>
</ibecs-document>
